Pathophysiological Sex Differences in Heart Failure Progression AfterAcute Coronary Syndrome: Insights From the EXAMINE Trial

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • João Pedro Melo Marques Pinho Ferreira

    Autor

Participantes de fora da FMUP

  • Razaghizad, A
  • Aziz, H
  • Zhang, GK
  • White, WB
  • Mehta, CR
  • Bakris, GL
  • Zannad, F
  • Sharma, A

Unidades de investigação

Abstract

Background: Therapies can reduce the risk of heart failure (HF) development and progression in type 2 diabetes; nevertheless, the risk of these outcomes is greater in females than in males. Methods and Results: To investigate sex differences in HF development and progression, we compared baseline circulating proteins (Olink Cardiovascular II panel) in males and females with type 2 diabetes and recent acute coronary syndrome for the outcome of HF hospitalization. Data were from the placebo-controlled Examination of Cardiovascular Outcomes with Alogliptin vs Standard of Care (EXAMINE) trial. Pathophysiological sex-differences were interpreted with network and pathway over-representation analyses. The EXAMINE trial enrolled 5380 participants (32.1% females) with biomarker data available for 95.4% of individuals. Analyses revealed 43 biomarkers were differentially expressed in HF hospitalization, of which 18 were sex specific. Among these 43 biomarkers, interleukin-6 was identified as a central node for the pathogenesis of HF hospitalization in both females and in males. Additional pathway over-representation analyses demonstrated that biomarkers associated with inflammatory pathways related to endothelial dysfunction and cardiac fibrosis were more up-regulated in females than males with HF hospitalization. Differential expression of 3 biomarkers (pentraxin-related protein 3, hydroxyacid oxidase 1, and carbonic anhydrase 5A) was independently associated with an increased risk of HF hospitalization in females but not in males (interaction P < .05). Conclusions: In males and females with type 2 diabetes and acute coronary syndrome, interleukin-6 seems to be central in the pathogenesis of HF. Females exhibit higher levels of circulating proteins related to immunological pathways, reflecting sex-specific differences underlying HF development and progression.

Dados da publicação

ISSN/ISSNe:
1071-9164, 1532-8414

Journal of Cardiac Failure  Churchill Livingstone

Tipo:
Article
Páginas:
767-777
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 3

Citações Recebidas na Scopus: 3

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Proteomics; heart failure; diabetes; epidemiology; sex differences

Financiamento

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023

Citar a publicação

Partilhar a publicação